August 31, 2020 -- Arrakis Therapeutics is touting the publication of a new paper that demonstrates the capabilities of its proprietary Photoaffinity Evaluation of RNA Ligation-sequencing (PEARL-seq) technology for the systemic identification of binding sites in RNA molecules as a method to facilitate the discovery of RNA-targeted small molecule medicines. The research was published in the American Chemical Society's ACS Chemical Biology.
The company's PEARL-seq utilizes photoaffinity labeling of RNA in combination with next-generation sequencing and a dedicated bioinformatic analysis pipeline. The data shows that the PEARL-seq platform was able to identify ligand binding sites within a model aptamer RNA and identify potential off-target binding interactions.
The platform -- in combination with conventional RNA structure probing methods -- can be used to generate and refine 2D and 3D structures of RNA-small molecule complexes to facilitate the rational design of RNA-targeted small molecule therapeutics, according to the company.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
